These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 3876976)

  • 21. Non lymphoblastic T cell lymphomas with prevalent skin involvement different from mycosis fungoides or Sézary's syndrome. A retrospective study of 6 cases in Europe.
    Grob JJ; Horchowski N; Tubiana N; Gabriel B; Gastaut JA; Hassoun J; Jouve I; Carcassone Y; Bonerandi JJ
    Dermatologica; 1988; 177(2):82-97. PubMed ID: 3262542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK; Mullins FM; Kim YH; Kong CS
    Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dermatopathic lymphadenopathy. An immunophenotypic comparison of cases associated and unassociated with mycosis fungoides.
    Burke JS; Sheibani K; Rappaport H
    Am J Pathol; 1986 May; 123(2):256-63. PubMed ID: 3486598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
    Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
    Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
    Toro JR; Stoll HL; Stomper PC; Oseroff AR
    J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
    Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
    Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further evidence for the T-cell nature of the atypical mononuclear cells in mycosis fungoides.
    van Leeuwen AW; Meijer CJ; van Vloten WA; Scheffer E; de Man JC
    Virchows Arch B Cell Pathol; 1976 Sep; 21(3):179-87. PubMed ID: 823699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes.
    Shapiro PE; Pinto FJ
    Am J Surg Pathol; 1994 Jul; 18(7):645-67. PubMed ID: 8017560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome.
    Calvani J; de Masson A; de Margerie-Mellon C; de Kerviler É; Ram-Wolff C; Gruber A; Meignin V; Brice P; Sadoux A; Mourah S; Bagot M; Battistella M
    Br J Dermatol; 2021 Aug; 185(2):419-427. PubMed ID: 33400272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features of cutaneous T-cell lymphoma.
    Abel EA
    Dermatol Clin; 1985 Oct; 3(4):647-64. PubMed ID: 2878755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic morphometry of isolated lymph node cells from patients with mycosis fungoides and Sézary's syndrome.
    van der Loo EM; Cornelisse CJ; van Vloten WA; van der Velde EA; Scheffer E; Meijer CJ
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1980; 33(2):107-16. PubMed ID: 6109394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node histopathologic findings in cutaneous T-cell lymphoma. A prognostic classification system based on morphologic assessment.
    Vonderheid EC; Diamond LW; Lai SM; Au F; Dellavecchia MA
    Am J Clin Pathol; 1992 Jan; 97(1):121-9. PubMed ID: 1728853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dermatopathic lymphadenopathy. Comparison of cases associated and unassociated with mycosis fungoides.
    Burke JS; Colby TV
    Am J Surg Pathol; 1981 Jun; 5(4):343-52. PubMed ID: 7270782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.